Vol 60, No 4 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Biochemical markers of myocardial damage after radiofrequency ablation

Jacek Bednarek, Igor Tomala, Jacek Majewski, Jacek Szczepkowski, Jacek Lelakowski
Kardiol Pol 2004;60(4):339-341.
Vol 60, No 4 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Radiofrequency catheter ablation (RFCA) may cause myocardial injury.
Aim: To assess changes in myocardial enzymes levels following RFCA.
Methods: Creatine kinase (CK), CK-MB, aspartate aminotransferase (GOT), alanine aminotransferase (GPT), troponin I and myoglobin levels were assessed in 53 patients (33 females, 20 males, mean age 53 years, range 23-78 years) before and 20 hours after successful RFCA (WPW type A = 13, WPW type B = 10, atrio-ventricular nodal tachycardia n = 17, atrial fibrillation or flutter n = 5, atrial tachycardia n = 2 and complex arrhythmias n = 6).
Results: The mean number of RF applications was 10.4, cumulative energy - 22 671 J, duration of application - 468 sec, and temperature - 58° C. A significant post-RFCA increase in the troponin I and myoglobin levels was found whereas the changes in CK and GOT levels were less pronounced. A significant correlation between troponin I elevation and RFCA energy, particularly in males, was documented. There was a trend towards a decrease in the GPT and CK-MB levels. Troponin I and myoglobin levels increased regardless of the site of RF energy application.
Conclusions: Troponin I and myoglobin are useful for the assessment of RFCA-induced myocardial injury, regardless of the site of RFCA application.

Abstract

Background: Radiofrequency catheter ablation (RFCA) may cause myocardial injury.
Aim: To assess changes in myocardial enzymes levels following RFCA.
Methods: Creatine kinase (CK), CK-MB, aspartate aminotransferase (GOT), alanine aminotransferase (GPT), troponin I and myoglobin levels were assessed in 53 patients (33 females, 20 males, mean age 53 years, range 23-78 years) before and 20 hours after successful RFCA (WPW type A = 13, WPW type B = 10, atrio-ventricular nodal tachycardia n = 17, atrial fibrillation or flutter n = 5, atrial tachycardia n = 2 and complex arrhythmias n = 6).
Results: The mean number of RF applications was 10.4, cumulative energy - 22 671 J, duration of application - 468 sec, and temperature - 58° C. A significant post-RFCA increase in the troponin I and myoglobin levels was found whereas the changes in CK and GOT levels were less pronounced. A significant correlation between troponin I elevation and RFCA energy, particularly in males, was documented. There was a trend towards a decrease in the GPT and CK-MB levels. Troponin I and myoglobin levels increased regardless of the site of RF energy application.
Conclusions: Troponin I and myoglobin are useful for the assessment of RFCA-induced myocardial injury, regardless of the site of RFCA application.
Get Citation

Keywords

radiofrequency application - myocardial injury - cardiac enzymes

About this article
Title

Biochemical markers of myocardial damage after radiofrequency ablation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 60, No 4 (2004)

Pages

339-341

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2004;60(4):339-341.

Keywords

radiofrequency application - myocardial injury - cardiac enzymes

Authors

Jacek Bednarek
Igor Tomala
Jacek Majewski
Jacek Szczepkowski
Jacek Lelakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl